US 11,952,421 B2
Bispecific antibodies against CD3EPSILON and ROR1
Minh Diem Vu, Wollerau (CH); Klaus Strein, Weinheim (DE); Oliver Ast, Bassersdorf (CH); Tanja Fauti, Zurich (CH); Anne Freimoser-Grundschober, Zurich (CH); Ralf Hosse, Cham (CH); Christian Klein, Bonstetten (CH); Ekkehard Moessner, Kreuzlingen (CH); Samuel Moser, Rotkreuz (CH); Ramona Murr, Zurich (CH); Pablo Umana, Wollerau (CH); Sabine Jung-Imhof, Planegg (DE); Stefan Klostermann, Neuried (DE); Michael Molhoj, Munich (DE); Joerg Regula, Munich (DE); and Wolfgang Schaefer, Mannheim (DE)
Assigned to Bristol-Myers Squibb Company, Princeton, NJ (US)
Appl. No. 15/517,296
Filed by BRISTOL-MYERS SQUIBB COMPANY, Princeton, NJ (US)
PCT Filed Oct. 8, 2015, PCT No. PCT/EP2015/073308
§ 371(c)(1), (2) Date Apr. 6, 2017,
PCT Pub. No. WO2016/055592, PCT Pub. Date Apr. 14, 2016.
Claims priority of application No. 14188378 (EP), filed on Oct. 9, 2014; and application No. 14188727 (EP), filed on Oct. 14, 2014.
Prior Publication US 2017/0306018 A1, Oct. 26, 2017
Int. Cl. A61K 39/00 (2006.01); C07K 16/28 (2006.01)
CPC C07K 16/2809 (2013.01) [C07K 16/2803 (2013.01); A61K 2039/505 (2013.01); C07K 2317/31 (2013.01); C07K 2317/64 (2013.01); C07K 2317/73 (2013.01); C07K 2317/77 (2013.01)] 6 Claims
 
1. A bispecific antibody which specifically binds human CD3ε comprising SEQ ID NO: 63 and an extracellular domain of human ROR1 comprising SEQ ID NO: 1, said bispecific antibody comprising:
(a) heavy chain polypeptides of SEQ ID NO: 37 and SEQ ID NO: 38, and light chain polypeptides of SEQ ID NO: 39 and SEQ ID NO: 40; or
(b) heavy chain polypeptides of SEQ ID NO: 37 and SEQ ID NO: 38, and light chain polypeptides of SEQ ID NO: 39 and SEQ ID NO: 41.